Revenue segments as reported by the company.

Smokeable Products

Oral Tobacco Products

Wine

All Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, administration and research costs

Asset impairment and exit costs

Amortization of intangibles

General corporate expenses

Corporate asset impairment and exit costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Altria

Altria Group, Inc. operates as a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral tobacco products, and Wine. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral tobacco products segment is primarily moist smokeless tobacco products (MSTs) through brands like Copenhagen and Skoal as well as on! oral nicotine pouches sold by Helix. The Wine segment, through subsidiary Ste. Michelle Wine Estates Ltd, produces Washington State wines, primarily Chateau Ste. Michelle and 14 Hands, and owns wineries in or distributes wines from several other wine regions. The company was founded in 1919 and is headquartered in Richmond, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Altria reports robust Q4 earnings, focuses on innovation and growth

Altria's Q4 2022 performance reflects resilience amidst industry challenges, with a focus on innovation and shareholder returns. The company's strategic initiatives in smoke-free products and digital engagement underscore its commitment to long-term growth and harm reduction.

Altria reports resilient Q1 performance amid industry challenges and opportunities

Altria's Q1 2023 earnings call highlighted strong performance amidst industry challenges, emphasizing harm reduction and regulatory compliance. The company faces hurdles from inflation, regulatory changes, and evolving consumer behaviors, while focusing on growth opportunities in smoke-free products and strategic investments.

Altria reports solid Q2 earnings, eyes e-vapor growth opportunities

Altria's focus on smoke-free products and NJOY acquisition driving growth.
Challenges in the cigarette industry due to economic pressures and flavor bans.
Opportunities in the e-vapor category and expansion plans in the U.S.
Strong balance sheet and significant capital returns to shareholders.

Altria reports growth in earnings, navigates regulatory challenges in e-vapor

Altria's Q3 2023 earnings call highlighted solid financial performance, strategic focus on e-vapor products, and efforts to combat illegal vape products. The company faces challenges from regulatory uncertainties and illicit products but sees opportunities in expanding NJOY's reach and addressing market gaps.

Altria reports growth in smoke-free products amidst regulatory challenges

Altria's Q4 2023 earnings call highlighted growth in adjusted EPS, strategic focus on smoke-free products, and efforts to combat illicit e-vapor products. The company faces challenges in competitive segments and economic pressures but sees opportunities in new product introductions and regulatory collaborations.

Altria reports mixed Q1 performance, focuses on growth strategies

Altria's Q1 performance showed growth in NJOY and oral tobacco segments, with challenges in EPS decline and economic pressures on consumers.
Strengths include reaffirmed EPS guidance, strategic investments, and focus on combating illicit e-vapor products.
Opportunities lie in maximizing profitability in oral tobacco, product positioning, and capturing transitioning consumers.
Overall, Altria's performance reflects a mix of growth, challenges, and strategic opportunities in navigating market dynamics.

Altria's NJOY drives growth as company navigates e-vapor challenges

Altria's Q2 2024 earnings call showcased strong performance in smoke-free products, highlighting growth in retail share and volume momentum. Despite challenges in the e-vapor category, the company remains focused on responsible regulation and enforcement. With a commitment to shareholder value and long-term growth strategies, Altria is poised for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.

Philip Morris

Buyers returned to tobacco stocks last week on hopes that smokeless products may offset declining cigarette volumes.

Tobacco Stocks Gain Amid Heat-Not-Burn Product Growth

U.S. regulators have opened a probe regarding Marlboro maker Altria Group Inc's  investment in e-cigarette maker Juul Labs Inc, according to a person familiar with the matter.

U.S. SEC probes Altria's investment in Juul: source

The federal agency is concerned that the tobacco giant failed to adequately disclose the risk it was taking with investing in JUUL.

SEC Reportedly Probing Altria's $12.8 Billion Stake in E-Cigarette Maker JUUL

The companies are the subject of several investigations by government agencies and regulators.

SEC Launches Probe Into Altria's Juul Investment

The Securities and Exchange Commission has launched an investigation into Altria's investment in e-cigarette start-up Juul Labs, the Wall Street Journal reported on Friday.

SEC reportedly probing Altria's Juul investment

U.S. regulators have opened a probe regarding Marlboro maker Altria Group Inc's  investment in e-cigarette maker Juul Labs Inc, the Wall Street Journal reported on Friday, citing people familiar with the matter.

U.S. SEC probes Altria's investment in Juul: WSJ

The tobacco company still believes it will improve profitability by 4% to 7% over its next three fiscal years.

Altria Reaffirms Guidance, 3-Year EPS Growth Target

Caterpillar

General Dynamics

W.W. Grainger

Meredith

Polaris

The 6 Best Dividend Aristocrats To Buy For 2020

The cigarette maker is reeling from its disastrous investment in JUUL. But the dividend looks safe.

Can Altria Sustain its Massive Dividend?

British American Tobacco

The debt financing keeps the lights on for now, but there are other challenges beyond money.

Can Juul Survive Even After a $700 Million Loan?

Canopy Growth

Cronos Group

Constellation Brands

Brand-name companies are finding little early-stage success in the high-growth cannabis industry.

Let's Face It, Marijuana Equity Investments Have Flopped

Boyd Gaming

Diageo

Raytheon

Almost regardless of what happens these days, the market pushes higher. Impeach the president?

5 Sin Stocks to Buy That May Survive a Massive Market Sell-Off

Discover

Johnson & Johnson

Public Storage

Texas Instruments

Exxon Mobil

These seven low-volatility stocks can help calm your nerves amid rising concerns regarding the coronavirus from China.

7 Low-Volatility Stocks to Buy In Jittery Times

Turning Point Brands

Vector Group

The move would strip the Food and Drug Administration of the duty it's held for more than a decade.

Trump Wants a New Agency to Oversee Tobacco Products

The funds are needed to replace the money Altria will no longer provide.

Juul Needs a $700 Million Loan as Altria Pulls Back

State legislators have also modified a bill that would have made the ban permanent.

Washington State's Ban on Flavored and THC Vapes Expires

Juul Labs Inc has raised more than $700 million in convertible debt from investors to fund its operations, a source familiar with the matter told Reuters, as the e-cigarette maker battles growing regulatory scrutiny on vaping.

Juul raises $700 million in debt from investors: source

Altria's shares fell on disappointing earnings.  However, a closer look suggests that the stock remains attractive for long-term investors.

Altria's Earnings: Bull Case Still Intact for This Dividend Growth Stock

The bans being considered extend far beyond e-cigs.

Juul Won't Be the Only One Hurt By a Ban on Flavored Tobacco Products

I Think Altria Has 20% Upside After Solid Q4 Results

Altria: E-Vapor Threat Reversed In Q4, Upgrade To Buy

After causing the tobacco giant to swing to a fourth-quarter loss, the e-cig leader's future isn't looking bright.

Altria Wipes Another $4.1 Billion Off Its JUUL Investment

Controversy surrounding the e-cigarette industry is costing the tobacco giant billions of dollars.

Altria's Profit Just Got Vaporized

Vitamin E acetate was among the agents found.

75% of Vapes Tested From Illegal Pot Shops in Los Angeles Contained Undisclosed Additives

Altria Group's (MO) CEO Howard Willard on Q4 2019 Results - Earnings Call Transcript

News for Altria Stock (MO)